Holen Sie sich die Stockscreener-App
4.15
1.74%
-0.10
Schlusskurs vom Vortag:
$4.25
Offen:
$4.16
24-Stunden-Volumen:
7,206
Relative Volume:
0.02
Marktkapitalisierung:
$100.50M
Einnahmen:
$68.38M
Nettoeinkommen (Verlust:
$-20.17M
KGV:
-4.6951
EPS:
-0.8839
Netto-Cashflow:
$-14.13M
1W Leistung:
-6.16%
1M Leistung:
-1.74%
6M Leistung:
-10.96%
1J Leistung:
-41.84%
1-Tages-Spanne:
$4.09
$4.184
1-Wochen-Bereich:
$4.05
$4.43
52-Wochen-Spanne:
$2.59
$12.23
Exagen Inc Stock (XGN) Company Profile
Firmenname
Exagen Inc
Sektor
Branche
Telefon
(760) 560-1501
Adresse
1261 LIBERTY WAY, VISTA, CA
Compare XGN vs TMO, DHR, IDXX, A, NTRA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
4.16 | 102.68M | 68.38M | -20.17M | -14.13M | -0.8839 |
TMO
Thermo Fisher Scientific Inc
|
534.58 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.94 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
568.63 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
133.88 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
266.75 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-11 | Eingeleitet | B. Riley Securities | Buy |
| 2025-07-30 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-07-23 | Eingeleitet | Craig Hallum | Buy |
| 2022-08-05 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-04-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Eingeleitet | Cowen | Outperform |
| 2019-10-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Exagen Inc Aktie (XGN) Neueste Nachrichten
ETFs Investing in Exagen, Inc. Stocks - TradingView
Exagen Inc focuses on autoimmune diagnostics as investors watch strategy - Ad Hoc News
Exagen Company Profile & Introduction - Moomoo
XGNExagen Inc Volatility & Greeks - Finviz
Exagen Inc. (XGN) Edges Higher as Stock Consolidates Near Key Support LevelNAAIM Leverage - dars.gov.et
Price to earnings forward of Exagen, Inc. – LS:A2PRXT - TradingView
Enterprise value to EBIT forward of Exagen Inc. – NASDAQ:XGN - TradingView
A2PRXT Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Exagen Inc. – NASDAQ:XGN - TradingView
Enterprise value to EBIT forward of Exagen, Inc. – GETTEX:E08A - TradingView
Enterprise value to EBITDA forward of Exagen Inc. – NASDAQ:XGN - TradingView
Price to sales forward of Exagen Inc. – NASDAQ:XGN - TradingView
Price to sales forward of Exagen, Inc. – GETTEX:E08A - TradingView
Enterprise value to revenue forward of Exagen Inc. – NASDAQ:XGN - TradingView
Enterprise value to revenue forward of Exagen Inc. – BOATS:XGN - TradingView
Exagen, Inc. Actuals & Estimates (NASDAQ:XGN) - TradingView
Exagen sets dates for second-quarter results, shares watched around Nasdaq listing - ad-hoc-news.de
E08A Forecast — Price Target — Prediction for 2027 - TradingView
XGN Forecast — Price Target — Prediction for 2027 - TradingView
XGN Initiates Coverage On Exagen -- Roth Capital Assigns Buy Rat - GuruFocus
XGN Q1 2026 Earnings: EPS Beat Drives Positive Stock MovementStrong Earnings Momentum - dars.gov.et
Exagen (XGN) Gains Buy Rating with $8 Price Target from Analyst - GuruFocus
Form 4 Exagen Inc For: 24 June By Investing.com - Investing.com Nigeria
Exagen Inc (XGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 4 Exagen Inc For: 22 June By Investing.com - Investing.com Australia
Exagen (XGN) director Scott Kahn receives 37,500 stock options grant - Stock Titan
Exagen (XGN) director granted 37,500 stock options at $4.31 strike - Stock Titan
Exagen (XGN) director Frank Stokes receives 37,500 stock options at $4.31 - Stock Titan
Exagen StockSunday background on autoimmune diagnostics specialist - AD HOC NEWS
Exagen advances use of new RA biomarkers to refine patient risk assessment - Traders Union
Exagen Inc (XGN) Institutional Confidence - TradingKey
XGN Q1 2026 Earnings: EPS Surprises with 15.15% Beat; Stock Gains 6.82%EPS Consistency Score - dars.gov.et
Exagen (XGN) Stock Draws Fresh Price Target Split After Analysts Trim Targets - Yahoo Finance
Exagen Inc (XGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exagen Inc (XGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exagen Inc (XGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Exagen Inc (XGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Exagen Inc (XGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Exagen Inc (XGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exagen Inc (XGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Exagen Inc. (XGN) Q1 2026 Earnings: Adjusted Loss Narrows, Stock Gains in AftermathSegment Revenue Breakdown - newsline.com
Exagen Shareholders Approve Directors, Auditor and Pay Package - The Globe and Mail
Exagen | 8-K: Current report - Moomoo
Exagen (NASDAQ: XGN) shareholders approve directors, auditor and say-on-pay - Stock Titan
XGN Q1 2026 Earnings: EPS Beats Estimates Despite Stock DeclineRevenue Surprise History - newsline.com
Exagen Inc. Q1 2026 Earnings: EPS Surprise Lifts but Revenue Disclosure Gap Weighs on SharesMargin Compression Risk - newsline.com
Exagen Inc. (XGN) Plunges 9.4% – Key Support Levels in Focus After Sharp SelloffIV Spike - newsline.com
Exagen study shows lupus test identifies 25% more patients By Investing.com - Investing.com South Africa
Exagen study shows lupus test identifies 25% more patients - Investing.com
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus - GlobeNewswire
Exagen Inc. (XGN) Q1 2026 Earnings: EPS Beats Estimates by 15.15%, Revenue Details Withheld, Stock DeclinesBook Value Growth - The Legal Advocate
Finanzdaten der Exagen Inc-Aktie (XGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.86%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):